Compare EPR Properties (EPR) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPR Properties vs TG Therapeutics Inc — how do they compare? EPR Properties trades at $61.8 (market cap $4.60B), while TG Therapeutics Inc trades at $54.85 (market cap $8.64B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and EPR Properties pays a 6.19% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| EPR | TGTX | |
|---|---|---|
Market Cap | $4.60B | $8.64B |
Sector | Real Estate | Health |
52-Week High | $60.81 | $59.06 |
52-Week Low | $48.71 | $26.39 |
Enterprise Value | $7.66B | $8.88B |
Dividend Yield | 6.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPR Properties trades at $61.76, up 3.73% today, with a bullish technical signal from moving averages and recent breakout above key levels. The REIT shows strong profitability with 39.93% net income margin and consistent dividend payments, though Q1 2026 EPS slightly missed expectations. Recent news highlights monthly dividend declarations and a $315 million Six Flags acquisition diversifying its experiential portfolio.
Outlook remains positive with analyst consensus target of $63.25 offering modest upside, supported by 99% occupancy and stable cash flows. Risks include economic sensitivity of entertainment assets and potential interest rate impacts on REIT valuations. The stock presents a balance of income and growth for investors seeking REIT exposure.
TG Therapeutics (TGTX) trades at $55.19, up 0.55% on the day, with a bullish technical signal from moving averages. The company shows strong profitability with a 65.95% net income margin and 112.6% ROE, though recent quarterly EPS has missed expectations. Positive clinical trial news for Briumvi in multiple sclerosis and schizophrenia is driving investor optimism and media coverage.
The outlook is supported by robust revenue growth and pipeline expansion, but risks include clinical trial execution and recent earnings volatility. Analysts are predominantly bullish with an 84.6% buy rating, though the consensus price target of $48.50 sits below the current price, suggesting potential near-term consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About EPR Properties
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
